Fondaparinux
- Generic Name
- Fondaparinux
- Brand Names
- Arixtra
- Drug Type
- Small Molecule
- Chemical Formula
- C31H53N3O49S8
- CAS Number
- 104993-28-4
- Unique Ingredient Identifier
- J177FOW5JL
- Background
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high...
- Indication
Approved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) tr...
- Associated Conditions
- Acute Pulmonary Embolism (PE), Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Segment Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis
- Associated Therapies
- -
Study to Determine Effective Dosing of Fondaparinux in Obese Persons
- Conditions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Indiana University School of Medicine
- Registration Number
- NCT00346879
- Locations
- 🇺🇸
Clarian Bariatric Center, Indianapolis, Indiana, United States
Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 127
- Registration Number
- NCT00333021
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00320424
- Locations
GSK Investigational Site
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 114
- Registration Number
- NCT00320398
- Locations
GSK Investigational Site
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Melbourne Health
- Target Recruit Count
- 20
- Registration Number
- NCT00256100
- Locations
- 🇦🇺
The Royal Melbourne Hospital Intensive Care Unit Grattan Street, Parkville, Victoria, Australia
Michelangelo - Oasis 5
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20078
- Registration Number
- NCT00139815
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 300
- Registration Number
- NCT00060554
- Locations
- 🇺🇸
UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇨🇦Sunnybrook & Women's College Health Sciences Center, Toronto, Ontario, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1309
- Registration Number
- NCT00038961
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.